Forest's COPD Candidate Delivers
January 05, 2011 |
Forest Laboratories, Inc. (NYSE: FRX - News) and Almirall recently announced positive top line data on their chronic obstructive pulmonary disease (COPD) candidate, aclidinium bromide. Results were presented from a pivotal phase III study (ATTAIN) that compared the safety and efficacy of aclidinium bromide (200μg and 400μg dosed twice daily) with placebo.
FRX - News) and Almirall recently announced positive top line data on their chronic obstructive pulmonary disease (COPD) candidate, aclidinium bromide. Results were presented from a pivotal phase III study (ATTAIN) that compared the safety and efficacy of aclidinium bromide (200μg and 400μg dosed twice daily) with placebo.
Results from the six month double-blind placebo-controlled study, which was conducted in 828 patients with moderate to severe COPD, showed that aclidinium achieved its primary as well as secondary endpoints. The candidate was also found to be well tolerated. In late October 2010, Forest Labs and Almirall had presented positive top line results on aclidinium from another phase III study - ACCORD COPD II.
The companies also presented data from two phase IIb dose-ranging studies which compared fixed-dose combinations of aclidinium bromide + formoterol with aclidinium bromide alone, formoterol alone and placebo. The fixed dose combination achieved statistical significance compared to placebo in both studies. Forest Labs and Almirall intend to move the fixed dose combination into phase III studies in the second half of 2011.
Regulatory Filings in Mid-2011
Forest Labs and Almirall are on track to file for regulatory approval of aclidinium (as a monotherapy) in both the US and the EU in mid-2011. While US rights for aclidinium have been in-licensed by Forest Labs from Almirall, ex-US rights remain with Almirall.
Aclidinum’s approval would be a major boost for Forest Labs. The COPD market represents huge commercial potential – according to the World Health Organization (WHO), about 210 million people suffer from COPD across the world. We note that Forest Labs is currently seeking US Food and Drug Administration (FDA) approval for another COPD candidate, Daxas.
Neutral on Forest Labs
We currently have a Neutral recommendation on Forest Labs. We are concerned about long-term growth at Forest Labs, especially from 2012 when Lexapro is exposed to generic competition. That puts a lot of pressure on the pipeline to come through.
Read the full research report.